Treatment of substance use disorders in patients with chronic liver disease
Manisha Verma, Gerald Scott Winder – 24 August 2022
Mental health edition introduction
Sheila Eswaran – 24 August 2022
Treatment of substance use disorders in patients with chronic liver disease
Manisha Verma, Gerald Scott Winder – 24 August 2022
Contact tracing in acute hepatitis C: The source patient identification and group overlap therapy proof‐of‐concept pilot program
Benjamin Eckhardt, Yesenia Aponte‐Melendez, Shashi N. Kapadia, Pedro Mateu‐Gelabert – 24 August 2022
Reply
Alexander Queck, Michael Praktiknjo, Christian Jansen, Jonel Trebicka – 24 August 2022
Benefits of tailored hepatocellular carcinoma screening in patients with cirrhosis on cancer‐specific and overall mortality: A modeling approach
Massih Ningarhari, Abbas Mourad, Claire Delacôte, Line‐Carolle Ntandja Wandji, Guillaume Lassailly, Alexandre Louvet, Sébastien Dharancy, Philippe Mathurin, Sylvie Deuffic‐Burban – 24 August 2022 – To validate cancer screening programs, experts recommend estimating effects on case fatality rates (CFRs) and cancer‐specific mortality. This study evaluates hepatocellular carcinoma (HCC) screening in patients with cirrhosis for those outcomes using a modeling approach.
Letter to the editor: Metabolic dysfunction‐associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality
Hong‐Xia Li, Zhi‐Qin Xie, Zhao‐Ming Yang, Cai‐Xi Tang – 24 August 2022
Reply
Laurens A. Kleef, Robert J. Knegt, Willem Pieter Brouwer – 24 August 2022
Letter to the editor: Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS
Wenhao Luo, Yawen Wang, Ye Li, Taiping Zhang – 24 August 2022
Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy
Omar Alshuwaykh, Tami Daugherty, Amanda Cheung, Aparna Goel, Renumathy Dhanasekaran, T. Tara Ghaziani, Aijaz Ahmed, Deepti Dronamraju, Radhika Kumari, Allison Kwong, Mindie Nguyen, W. Ray Kim, Paul Yien Kwo – 24 August 2022 – Chronic hepatitis B virus (HBV) infection is the leading risk factor for hepatocellular carcinoma (HCC). The aim of this study was to explore the incidence of HCC in a cohort of subjects with HBV and correlate with HBV treatment current guidance. We identified 2846 subjects with HBV over the study period.